

PHARMACY SERVICES

SECTOR SNAPSHOT

/ 1//1 11/1 10/5-01

June 2019

BOURNE PARTNERS

Comp./Spec. Pharmacy – Transaction Comps

		Compounding/Specia	lty Pharmacy – Ti	ransaction	Comps				
D in millions Announced Date	Target	Geographic Location	Enterprise Value	LTM Revenue	LTM EBITDA	EV / LTM Revenue	EV / LTM EBITDA		
May-19	Belmar Pharmacy	Compounding pharmacy located in Golden, CO. Provides patient- specific preparations of various pharmaceutical products	MedEquity Capital, LLC; Webster Equity Partners	USA	NA	NA	NA	NA	N
May-19	Specialty Pharmacy Business Assets of Premier, Inc.	Comprises the specialty pharmacy business/operations and related assets of Premier, Inc.	Procare Pharmacy, L.L.C.	USA	\$42.3	NA	NA	NA	N,
Oct-18	Avella Specialty Pharmacy	Operates a chain of retail pharmacies that provide specialty medications to patients across the US	OptumRx / UnitedHealth Group	USA	NA	NA	NA	NA	N.
Nov-17	Salus Pharmacare Inc.	Specialty pharmacy offering medication management services to assisted living and LTC facilities	Centric Health Corporation	Canada	3.2	NA	\$0.5	NA	6.8
Aug-17	Quantum Pharma Plc	Develops, manufactures, and supplies niche pharmaceutical products to the retail pharmacy, pharmaceutical wholesaler, hospital, and homecare markets	Clinigen Group Plc	United Kingdom	199.9	\$119.5	8.2	1.7x	24.4
Apr-16	Diplomat Specialty Pharmacy of Los Angeles County, Inc.	Stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers	Diplomat Pharmacy, Inc.	USA	75.7	400.0	9.0	NM	8.4
Apr-16	Integrity Compounding Pharmacy, LLC	Develops and provides compounded pharmaceutical products	True Nature Holding, Inc.	USA	1.0	0.9	NA	1.1x	N
Oct-15	PharMEDium Healthcare Holdings, Inc.	Provides outsourced compounded sterile preparations to acute care hospitals	AmerisourceBergen Drug Corporation	USA	3,060.8	405.7	96.0	7.5x	31.9
May-15	AnazaoHealth Corporation	Specialty pharmacy that compounds patient-specific preparations for the nuclear medicine and pain management markets, as well as for drugs used in clinical trials	Fagron NV	USA	97.8	NA	16.3	NA	6.0
Jun-13	CarePoint Partners, LLC	Provides home infusion therapy and specialty pharmacy services for patients, families, and caregivers in the US	BioScrip, Inc.	USA	221.1	140.5	NA	1.6x	N
tes:				Median	\$86.7	\$140.5	\$9.0	1.6x	8.4
- Not Availab	le			Mean	462.7	213.3	26.0	3.0x	15.
1 - Not Meani	ngful			Min	1.0	0.9	0.5	1.1x	
				Max	3,060.8	405.7	96.0	7.5x	31.

BOURNE PARTNERS

PBM/Managed Care – Transaction Comps

in millions inounced Date	Target	Target Description	Buyer	Geographic Location	Enterprise Value	LTM Revenue	LTM EBITDA	EV / LTM Revenue	EV / LTN EBITDA
Mar-19	WellCare Health Plans, Inc.	Provides government-sponsored managed care services	Centene Corporation	USA	\$17,300.0	\$20,414.1	\$915.2	0.8x	18.
Sep-18	Genoa Healthcare, LLC	Genoa Healthcare is the largest provider of pharmacy, outpatient telepsychiatry and medication management services	OptumRx, Inc.	USA	2,500.0	NA	NA	NA	1
Aug-18	Excel Managed Care & Disability Services Inc.	Provides occupational and non-occupational medical case management, utilization review, and return-to-work services	Genex Services, LLC	USA	NA	NA	NA	NA	
Mar-18	RxAdvance Corporation	RxAdvance is a national full-service PBM that helps to manage standard formulary, specialty pharmaceutical, and biologics usage	Centene Corporation	USA	NA	NA	NA	NA	
Mar-18	Express Scripts Holding Company	Express Scripts is one of the largest PBMs in the US	Cigna Corporation	USA	68,671.4	100,064.6	7,132.5	0.7x	g
Nov-17	Leehar Distributors, Inc.	Provides pharmacy benefits services for health insurance agents and consultants; third party administrators; and self-insured organizations	s Diplomat Pharmacy, Inc.	USA	595.6	NA	NA	NA	
Nov-16	Integrated Prescription Solutions, Inc.	Provides PBM and ancillary healthcare services in the US	Mitchell International, Inc.	USA	NA	NA	NA	NA	
Mar-15	Catamaran Corporation	Provides PBM and Healthcare IT solutions to the healthcare benefits management industry across North America	OptumRx, Inc.	USA	13,385.5	21,581.9	845.7	0.6x	15
				USA _	405.0	NA	35.0	NA	11
5:				Median	\$2,500.0	\$21,581.9	\$880.4	0.8x	11
Not Availab	le			Mean	19,349.7	40,525.5	2,436.5	1.0x	12
Not Meani	ingful			Min	47.0	32.0	5.4	0.6x	٤
				Max	69,643.0	100,064.6	7,132.5	1.5x	1

BOURNE PARTNERS

Comp./Spec. Pharmacy – Trading Comps

		Comp	oundin	g/Speci	alty Ph	armac	y — Trad	ing Cor	nps					
USD in millions		LTM Margin Analysis					Enterprise Value/			Debt/				
Company	Ticker	Enterprise Value	Sales	EBITDA	EBIT	Gross Profit	EBITDA	EBIT	Sales	EBITDA	EBIT	Enterprise Value	Equity Value	EBITDA
BioScrip, Inc.	NasdaqGS:BIOS	\$830.1	\$719.3	\$41.9	\$19.7	12.5%	5.8%	2.7%	1.2x	19.8x	42.2x	64.5%	178.6%	12.8x
Diplomat Pharmacy, Inc.	NYSE:DPLO	1,010.9	5,406.8	103.4	31.2	6.8%	1.9%	NM	0.2x	9.8x	32.4x	63.2%	170.4%	6.2x
Fagron NV	ENXTBR:FAGR	1,740.0	540.0	99.0	83.8	44.2%	18.3%	15.5%	3.2x	17.6x	20.8x	21.7%	26.0%	3.8x
Harrow Health, Inc.	NasdaqCM:HROW	150.9	44.8	(1.5)	(3.4)	63.5%	NM	NM	3.4x	NM	NM	14.0%	13.0%	NM
					Median	28.3%	5.8%	9.1%	2.2x	17.6x	32.4x	42.5%	98.2%	6.2x
					Mean	31.7%	8.7%	9.1%	2.0x	15.7x	31.8x	40.9%	97.0%	7.6x
					Min	6.8%	1.9%	2.7%	0.2x	9.8x	20.8x	14.0%	13.0%	3.8x
					Max	63.5%	18.3%	15.5%	3.4x	19.8x	42.2x	64.5%	178.6%	12.8x


- Few pure-play, publicly traded Compounding/Specialty Pharmacies exist on the market today
- As these markets continue to mature and experience consolidation, we expect to see more companies looking to the public markets as a capital source
- This segment of the market saw increased valuations over Q1 2019, due in part to increased interest from Private Equity as illustrated by the acquisition of Belmar Pharmacy
- Also throughout Q2, Compounders continued to endure the scrutiny of the FDA and its requirements for sterile compounding
- The median EV multiples for this sector are 2.2x and 17.6x for LTM Sales and EBITDA, respectively

PBM/Managed Care – Trading Comps

USD in millions		_	LTM			Margin Analysis			Enterprise Value/			Debt/		
Company	Ticker	Enterprise Value	Sales	EBITDA	EBIT	Gross Profit	EBITDA	EBIT	Sales	EBITDA	EBIT	Enterprise Value	Equity Value	EBITDA
Anthem, Inc.	NYSE:ANTM	\$91,047.1	\$94,220.0	\$6,530.0	\$5,966.0	21.3%	6.9%	6.3%	1.0x	13.9x	15.3x	22.7%	27.5%	3.2
Centene Corporation	NYSE:CNC	24,159.7	61,028.0	2,877.0	2,331.0	18.2%	4.7%	3.8%	0.4x	8.4x	10.4x	31.5%	33.3%	2.6
Cigna Corporation	NYSE:CI	96,812.4	75,145.0	6,983.0	5,870.0	24.6%	9.3%	7.8%	1.3x	13.9x	16.5x	42.5%	67.9%	5.9
CVS Health Corporation	NYSE:CVS	157,210.1	209,623.0	13,633.0	10,448.0	16.6%	6.5%	5.0%	0.7x	11.5x	15.0x	60.8%	136.5%	7.0
Humana Inc.	NYSE:HUM	37,772.1	58,740.0	3,420.0	3,187.0	18.8%	5.8%	5.4%	0.6x	11.0x	11.9x	17.7%	19.2%	2.0
WellCare Health Plans, Inc.	NYSE:WCG	14,013.1	22,530.1	996.3	862.2	14.5%	4.4%	3.8%	0.6x	14.1x	16.3x	17.1%	16.1%	2.4
					Median	18.8%	6.5%	5.4%	0.7x	13.1x	15.0x	22.7%	27.5%	2.6
					Mean	19.7%	6.6%	5.7%	0.8x	12.3x	14.2x	29.6%	45.3%	3.6
					Min	14.5%	4.4%	3.8%	0.4x	8.4x	10.4x	14.7%	16.1%	1.9
					Max	24.6%	9.3%	7.8%	1.3x	14.1x	16.5x	60.8%	136.5%	7.0

- Following the same trend as the year prior, 2019 has already been marked by its own mega-deal the \$17.3bn proposed acquisition of WellCare Health Plans by Centene Corporation – highlighting an ever-increasing focus on consolidation within this industry segment
 - The spike in M&A over the last handful of years has driven valuations and will likely continue to do so within the PBM segment as firms look to add niche services and compile more lives
- Median EV multiples for this segment are currently 0.7x and 13.1x for LTM Sales and EBITDA, respectively

Valuation Trends – Last 3 Years



- The PBM/Managed Care segment has seen a steady rise over the last 3 years, largely in line with the S&P 500
 - The sector is currently sitting at 12.7x LTM EBITDA
- The Compounding/Specialty Pharmacy index, despite sitting well above the S&P 500 over the last three years, has fallen closer in line with the broader market over the last few months
 - The sector is currently sitting at 14.7x LTM EBITDA

Comp./Spec. Pharmacy basket consists of: BioScrip, Inc. (NasdaqGS:BIOS), Diplomat Pharmacy, Inc. (NYSE:DPLO), Fagron NV (ENXTBR:FAGR), and Harrow Health, Inc. (NasdaqCM:HROW) PBM/Managed Care basket consists of: Anthem, Inc. (NYSE:ANTM), Centene Corporation (NYSE:CNC), Cigna Corporation (NYSE:CI), CVS Health Corporation (NYSE:CVS), Humana Inc. (NYSE:HUM), UnitedHealth Group Incorporated (NYSE:UNH), WellCare Health Plans, Inc. (NYSE:WCG)

Valuation Trends (Current, 3 Year, & LTM Comparisons)

- Below are the current TEV / EBITDA multiples for each sector:
 - Compounding/Specialty Pharmacy: 14.7x (14.7% above current S&P multiples)
 - PBM/Managed Care: 12.7x (0.6% below current S&P multiples)
 - S&P 500: 12.8x
- Below are the average TEV / EBITDA multiples for each sector over the last 3 years:
 - Compounding/Specialty Pharmacy: 19.1x (56.2% above average S&P multiples)
 - PBM/Managed Care: 11.4x (7.1% below average S&P multiples)
 - S&P 500: 12.2x
- Below are the % change in TEV / EBITDA multiples for each sector over the last 3 years (and LTM):
 - Compounding/Specialty Pharmacy: -31.1% (down 36.9% in the last 12 months)
 - PBM/Managed Care: +18.1% (up 8.3% in the last 12 months)
 - S&P 500: +16.7% (unchanged in the last 12 months)